JournalofChemicalHealthRisks

www.jchr.org

JCHR (2024) 14(5), 636-644 | ISSN:2251-6727

Multimodality Treatment for Sudden Sensoryneural Hearing Loss

Dr M K Rajasekar[1], Dr R P Jayapreetha[1], Dr Rajeshwari[1], Dr H L Manojji[1]

[1]Sree Balaji Medical College and Hospital, Chennai, Tamil Nadu, INDIA 600044

Corresponding author: Dr R P Jayapreetha, Senior resident, Sree Balaji Medical College and Hospital, INDIA

(**Received**:14 June 2024 **Revised**: 01 July 2024 **Accepted**: 18 August 2024)

KEYWORDS
sensorineural, etiology, Hyperbaric oxygen, cochlear,

ABSTRACT:

Sudden sensorineural hearing loss (SSNHL) is an acute, often unilateral condition marked by a rapid onset of hearing loss, typically occurring within 72 hours. Its etiology remains unclear in many cases, which complicates diagnosis and treatment. SSNHL management requires a comprehensive, multimodal approach to improve recovery rates and patient outcomes. Pharmacotherapy, particularly the use of systemic and intratympanic corticosteroids, is the first-line treatment aimed at reducing inflammation and edema in the cochlea. Hyperbaric oxygen therapy (HBOT) has shown promise when combined with corticosteroids, enhancing oxygen delivery to the inner ear. Antiviral and anticoagulant therapies may also be considered in specific cases where viral infections or coagulation abnormalities are suspected, although their efficacy remains debated. Rehabilitative strategies, including hearing aids and cochlear implants, play a crucial role in addressing residual hearing loss. Emerging therapies such as regenerative medicine, novel pharmacologic agents, and stellate ganglion block (SGB) are currently under investigation, offering hope for more targeted and effective treatments in the future. This article provides a comprehensive review of these multimodal treatment strategies, offering insight into both established and experimental approaches for managing SSNHL and highlighting the importance of early intervention for optimal outcomes.

Introduction

Sudden sensorineural hearing loss (SSNHL) is a perplexing and often distressing condition characterized by an unexplained, rapid-onset loss of hearing, typically in one ear. The sudden nature of the hearing loss, coupled with the uncertainty of its cause and the variability in patient outcomes, makes SSNHL a challenging condition to treat. It is usually defined as a hearing loss of at least 30 decibels over three contiguous frequencies, occurring within 72 hours. The exact cause is often idiopathic, though it is believed to involve viral infections, vascular compromise, or autoimmune responses affecting the inner ear, specifically the cochlea.

The treatment for SSNHL is not standardized, but multimodal approaches combining various therapeutic strategies have shown promise. While pharmacotherapy remains a cornerstone of treatment, other options such as hyperbaric oxygen therapy, rehabilitative strategies, and even emerging interventions like regenerative medicine and stellate ganglion blocks are being explored for their potential benefits.

Pharmacotherapy

1. Systemic Corticosteroids

Systemic corticosteroids, such as prednisone, are widely regarded as the first-line treatment for SSNHL. These drugs are believed to reduce inflammation and edema in the cochlea, which may be contributing to the hearing loss. Early initiation of corticosteroid therapy is crucial, as studies indicate that administering steroids within the first two weeks of symptom onset significantly improves hearing recovery. Inflammation in the cochlea could lead to damage of the delicate hair cells responsible for transmitting sound to the brain, and corticosteroids may mitigate this damage by reducing swelling and preventing further degradation of the auditory structures [1,2]. It is widely accepted that patients who receive corticosteroid treatment within this critical two-week window are more likely to experience partial or full recovery of their hearing, highlighting the importance of early detection and intervention.

2. Intratympanic Steroid Injections

For patients who do not respond to systemic corticosteroids or for those who cannot tolerate the side effects of oral or intravenous steroids, intratympanic steroid injections offer an effective alternative. This procedure involves injecting steroids directly into the middle ear, where they can then diffuse into the inner ear and cochlea. By delivering the medication directly to the

JournalofChemicalHealthRisks

www.jchr.org

JCHR (2024) 14(5), 636-644 | ISSN:2251-6727

site of damage, intratympanic injections offer the potential to maximize the therapeutic effects while minimizing systemic side effects such as weight gain, elevated blood sugar, or immune suppression [3,4]. In clinical practice, this approach is often used either as an adjunct to systemic therapy or as a standalone treatment in cases where systemic steroids are contraindicated.

Hyperbaric Oxygen Therapy (HBOT)

Hyperbaric oxygen therapy (HBOT) is another treatment option that has shown promise in improving outcomes for SSNHL patients, particularly when combined with corticosteroid therapy. HBOT involves breathing pure oxygen in a pressurized environment, which enhances the amount of oxygen delivered to tissues, including the damaged structures in the inner ear. The rationale behind this treatment is that increasing oxygen delivery to the cochlea can improve its function, especially if hypoxia (a lack of oxygen) has contributed to the hearing loss. HBOT is believed to promote healing by reducing oxidative stress, improving blood flow, and aiding in tissue repair [5,6]. As with corticosteroids, early intervention is critical, with studies suggesting that HBOT is most effective when initiated within the first two weeks of hearing loss.

Antiviral and Anticoagulant Therapy

The role of antiviral and anticoagulant therapies in treating SSNHL remains a subject of debate. Some cases of SSNHL may be caused by viral infections, particularly those involving the herpes simplex virus. In these cases, antiviral medications like acyclovir may be considered, although clinical evidence supporting their efficacy is mixed [7]. Similarly, there is speculation that SSNHL may be linked to vascular issues such as small blood clots or other coagulation abnormalities. In such cases, anticoagulant therapy might be beneficial, although trials investigating the use of anticoagulants in SSNHL have not consistently demonstrated significant improvements in hearing recovery [8]. These treatments are typically reserved for patients with specific risk factors or suspected underlying viral or vascular causes.

Rehabilitative Strategies

In cases where pharmacological treatments do not fully restore hearing, audiologic rehabilitation becomes essential. For patients with incomplete recovery, hearing aids and cochlear implants can significantly enhance their quality of life. Early audiological assessment is important to determine the extent of hearing loss and the best course of action for rehabilitation. Hearing aids may be effective for mild to moderate hearing loss, while cochlear implants are typically reserved for patients with more profound hearing loss who do not benefit from traditional hearing aids [9,10]. Rehabilitative efforts focus not only on restoring hearing but also on addressing the psychological and social impacts of hearing loss, which can be significant.

Emerging Therapies

Research into new treatments for SSNHL is ongoing, and several promising avenues are being explored. One such area is regenerative medicine, which aims to restore hearing through the regeneration of hair cells in the cochlea. Hair cells do not naturally regenerate in humans, and their loss is a major contributor to permanent hearing impairment. Advances in gene therapy and stem cell research offer hope that future treatments may be able to reverse hearing loss by regenerating these critical cells [11]. Clinical trials are also investigating novel pharmacologic agents that target specific pathways involved in hearing loss, with the goal of developing more effective treatments that go beyond the broad mechanisms of corticosteroids [12].

Stellate Ganglion Block (SGB)

Stellate ganglion block (SGB) is an emerging intervention for SSNHL, traditionally used for various pain syndromes. The stellate ganglion, located in the neck, is a collection of sympathetic nerves that regulate blood flow and neural activity in the head and upper limbs. The hypothesis behind using SGB for SSNHL is based on its ability to improve microcirculation to the inner ear, reduce inflammation, and alleviate pain. By blocking sympathetic nerve activity, SGB may enhance blood flow to the cochlea, improving oxygen and nutrient delivery to the damaged tissues [3,4]. Additionally, the anti-inflammatory effects of the procedure could help reduce swelling in the cochlea, potentially improving hearing outcomes. SGB is performed by injecting local anesthetic agents or steroids into or near the stellate ganglion, thereby modulating the autonomic nervous system and potentially benefiting patients with vascular or inflammatory components to their hearing loss.

Mechanism of Action of Stellate Ganglion Block

SGB works by targeting the autonomic nervous system, specifically by blocking sympathetic nerve transmission to the inner ear. When the sympathetic nervous system is

JournalofChemicalHealthRisks

www.jchr.org

JCHR (2024) 14(5), 636-644 | ISSN:2251-6727

overly active, it can constrict blood vessels and reduce blood flow to the cochlea, depriving it of essential oxygen and nutrients. By injecting a local anesthetic such as lidocaine or a steroid like dexamethasone near the stellate ganglion, SGB can inhibit this sympathetic activity, leading to improved circulation. Steroids used in the procedure may also provide additional therapeutic benefits by reducing inflammation and helping to repair damaged tissues.

CASE HISTORY

Patient 32 year male came with complaint of sudden hearing loss for 2 days, which was sudden in onset, Patient complaint of decreased hearing in Right ear which was instantaneous in onset with no preceding symptoms or warning signs. The hearing loss has remained constant since the onset; there has been no improvement or worsening.

Associated Symptoms: The patient reports no tinnitus, vertigo, or aural fullness. There is no facial weakness or other neurological symptoms. The patient has no history of recent trauma or exposure to loud noise. Additionally, there have been no recent upper respiratory infections or illnesses. He mentioned having a minor cold about two weeks ago, which resolved without complications. The patient is not a known case of diabetes mellitus, hypertension, or tuberculosis (TB). Overall, the medical history does not suggest any underlying conditions or recent events that could contribute to the current symptoms, if any.

Local Examination: The examination of the ears reveals normal findings in both the right and left pinna, external auditory canals (EAC), postauricular, and preauricular regions. The tympanic membranes (TM) are intact bilaterally. The nose shows no external deformity, and both nostrils are clear. Upon examination of the throat, the lips, gums, teeth, and buccal mucosa appear normal. The anterior and posterior pillars are also normal, with bilateral tonsils graded at 1 without congestion. The posterior pharyngeal wall (PPW) is clear, indicating no signs of infection or abnormality. Overall, the ear, nose, and throat examinations are unremarkable.

Diagnostic Testing

Audiometry revealed severe sensorineural hearing loss in the right ear, indicating significant auditory impairment (Figure 1). To further investigate potential underlying causes, an MRI of the brain and temporal bones was performed, primarily to rule out structural abnormalities such as tumors, including acoustic neuroma. The imaging results showed no significant abnormalities. In addition to imaging, a series of laboratory tests were conducted, including a complete blood count (CBC), basic metabolic panel, and thyroid function tests. These tests aimed to identify any systemic conditions that could be contributing to the hearing loss. All laboratory results were within normal limits, ruling out common metabolic or thyroid-related causes for the patient's symptoms.



Figure 1. Pure tone audiometry

Treatment

The patient was diagnosed with sudden sensorineural hearing loss (SSNHL), which is considered a medical emergency. The standard treatment for SSNHL in a non-diabetic includes: (1) Intravenous methylprednisolone, 1

JournalofChemicalHealthRisks
www.jchr.org
JCHR (2024) 14(5), 636-644 | ISSN:2251-6727

gram per day for 3 days, followed by oral steroids at 1 mg/kg/day for 4 weeks with tapering; (2) antiviral therapy with either Acyclovir 800 mg five times daily or Valcivir 500 mg twice daily; and (3) intratympanic injection of dexamethasone in the right ear (Figure 2).



Figure 2. Intratympanic steroids injection

A pure tone audiogram performed after three days of IV steroid treatment showed improvement in hearing. The patient responded well to the initial therapy (Figure 3).



Figure 3. Pure tone audiogram after three days of IV steroid treatment

After three days, the patient underwent a stellate ganglion block on the right side (Figure 4).

JournalofChemicalHealthRisks

www.jchr.org

JCHR (2024) 14(5), 636-644 | ISSN:2251-6727



Figure 4. stellate ganglion block

Two days later, a pure tone audiometry was performed, which showed further improvement in hearing (Figure 5). The patient reported feeling better symptomatically, with noticeable improvements in hearing. The combined treatment approach, including the stellate ganglion block, appears to have positively impacted the patient's recovery.



Figure 5. Pure tone audiogram after two days of stellate ganglion block

In cases of sudden sensorineural hearing loss (SSNHL), various optional treatments may be considered depending on the patient's condition, especially if they have underlying issues like diabetes or hypertension. One treatment option is IV Lomodex, a blood-thinning agent administered every 12 hours, which improves circulation and reduces the likelihood of clot formation, potentially contributing to hearing loss recovery. Another option is Trental (Pentoxyfyline) 400 mg, which enhances blood flow by improving the flexibility of red blood cells, thereby promoting circulation to the inner ear. Nootropil (Piracetam) 400 mg, a neural tonic, may also be prescribed to enhance cognitive function and neural health, which could improve the function of the auditory nerve.

Complementary treatments may include Cap Palsinuron, an empirical Ayurvedic remedy, which could promote nerve health and healing. Tab Razo-L, an anti-acidity and reflux medication, can be prescribed to prevent gastrointestinal issues that might interfere with the absorption of other treatments. Carbogen, a vasodilator, may also be used to enhance blood flow to the inner ear, ensuring adequate oxygen supply for recovery.

JournalofChemicalHealthRisks

www.jchr.org

JCHR (2024) 14(5), 636-644 | ISSN:2251-6727

Additionally, Hyperbaric Oxygen Therapy (HBOT), if available, can be an effective option to increase oxygenation of the inner ear tissues, promoting healing and auditory function.

For patients with elevated blood sugar levels, it is critical to bring their blood sugar under control, as uncontrolled diabetes can affect recovery and worsen hearing loss. The therapeutic window for SSNHL typically ranges from four to six weeks, and early treatment is crucial for a successful outcome. In over 95% of cases, SSNHL is unilateral, affecting only one ear, with bilateral cases being quite rare. Approximately 65% of cases experience spontaneous recovery, with patients regaining hearing within 20dB or more than 50% of the total hearing loss, often within the first two weeks, which is a positive indicator for recovery. Despite this, the prognosis remains guarded, and the cause of SSNHL is idiopathic in 85-90% of cases, meaning it remains unknown, and much of the treatment is empirical.

Given the high cost of treatments, which may include MRI and CT scans, some patients may opt for no treatment, particularly if the prognosis is uncertain or financial constraints play a role. Recurrent or progressive hearing loss could indicate inner ear defects, requiring further evaluation.

For rehabilitation in cases of permanent hearing loss, hearing aids can be difficult to use in patients with Single-Sided Deafness (SSD) because one ear remains normal while the other has profound hearing loss. An alternative to traditional hearing aids is Bone Anchored Hearing Aids (BAHA), which use either an external titanium abutment or an internal magnetic coupling. Devices like Cochlear, Medtronic (Sophono/Otomag), and Oticon offer such solutions. Transtympanic steroids, Carbogen, and HBOT can also be used as salvage procedures if available, with intratympanic steroids being continued for up to six weeks.

Tinnitus, if present, can be treated later with Caroverine (Tinnex) injections and capsules. With steroid treatment, the chances of recovery from SSNHL are around 50%. Key factors influencing prognosis include the timeline of intervention, the patient's age, the results of the Pure Tone Audiogram (PTA), the presence of vertigo or tinnitus, and underlying comorbidities such as diabetes, hypertension, and vascular issues.

Blood tests play an important role in evaluating the patient's overall health and include complete blood counts, erythrocyte sedimentation rate (ESR), blood sugar levels, thyroid function tests, coagulogram, homocysteine levels, lipid profiles, and tests for infectious diseases such as HIV and hepatitis. These tests help identify any underlying conditions that may affect the treatment plan or prognosis for SSNHL.

Discussion

The treatment of sudden sensorineural hearing loss (SSNHL) remains a challenging and evolving field due to the idiopathic nature of most cases. The multimodal approach used for treating SSNHL reflects the complexity of the condition and the need for individualized care plans tailored to each patient's circumstances [13,14]. From pharmacotherapy to emerging interventions like regenerative medicine and stellate ganglion block (SGB), the breadth of potential treatments underscores both the difficulty in managing SSNHL and the hope offered by new advancements [13,14,15].

Pharmacological treatments, particularly corticosteroids, have become a cornerstone in the management of SSNHL. Systemic corticosteroids like prednisone are widely regarded as the first-line treatment for this condition due to their ability to reduce inflammation and edema in the cochlea. Early initiation of corticosteroid therapy—within the first two weeks of symptom onset—has been shown to significantly improve hearing outcomes, emphasizing the importance of timely intervention. For patients who do not respond to systemic corticosteroids or cannot tolerate them, intratympanic steroid injections offer an effective alternative. These injections provide direct delivery of the medication to the cochlea, maximizing local therapeutic effects while minimizing systemic side effects. This targeted approach underscores the importance of personalized care in treating SSNHL [16,17]. The patient case in this study, which involved a rapid response to systemic and intratympanic steroids, highlights the efficacy of corticosteroids when administered promptly. As corticosteroids remain the primary treatment for SSNHL, their role in reducing cochlear inflammation and preserving auditory function continues to be supported by clinical practice and research.

Another significant treatment modality discussed is hyperbaric oxygen therapy (HBOT). The theory behind HBOT in SSNHL treatment involves the delivery of pure oxygen in a pressurized chamber, which enhances oxygenation of the cochlea, potentially reversing damage caused by hypoxia [18]. Studies have shown that HBOT,

JournalofChemicalHealthRisks

www.jchr.org

JCHR (2024) 14(5), 636-644 | ISSN:2251-6727

when combined with corticosteroids, can improve outcomes, particularly when administered early. The mechanism of action—promoting oxygen delivery, improving microcirculation, and reducing oxidative stress—is appealing, especially in patients who present with ischemic or hypoxic damage to the cochlea [19]. In the patient described in this case, the use of steroids, combined with other therapeutic options, showcased positive recovery trajectories. However, access to HBOT can be limited, and its cost can pose a challenge, particularly in settings where healthcare resources are constrained. Nevertheless, the growing body of evidence supporting HBOT in SSNHL treatment suggests it should be considered more broadly in appropriate clinical settings.

Among the newer and more experimental treatments for SSNHL, stellate ganglion block (SGB) and regenerative medicine offer intriguing possibilities. The SGB is an intervention traditionally used for pain management but has been explored for SSNHL due to its ability to modulate the sympathetic nervous system. By improving blood flow to the inner ear and reducing inflammation, SGB has the potential to enhance recovery in SSNHL patients [20]. Although evidence supporting its use is still limited, particularly in large-scale studies, early clinical reports have shown promising results, as observed in the patient discussed in this study. The use of SGB in this case—combined with corticosteroid therapy and other standard treatments—appeared to contribute to improved hearing outcomes, further supporting the idea that SGB may be a valuable adjunct in the treatment of SSNHL. As with any emerging treatment, further research and clinical trials are essential to confirm its efficacy and establish clear guidelines for its use in SSNHL.

Similarly, regenerative medicine, including gene therapy and stem cell research, represents a frontier of hope for patients with permanent hearing loss due to SSNHL. Current pharmacologic treatments, while effective in many cases, are largely aimed at reducing inflammation and preventing further damage rather than repairing the lost function of cochlear cells. By focusing on the regeneration of hair cells within the cochlea, regenerative therapies offer the possibility of not just mitigating damage but potentially reversing hearing loss. Although these therapies remain in the experimental stages, the potential they offer is substantial, especially for patients who fail to respond to traditional treatments [21].

Antiviral and anticoagulant therapies remain contentious in the treatment of SSNHL. In cases where a viral etiology, such as a herpes simplex virus infection, is suspected, antiviral drugs like acyclovir may be considered. However, clinical evidence supporting their efficacy is mixed, and antivirals are generally reserved for specific cases with strong viral indications [22]. Similarly, anticoagulant therapies are based on the hypothesis that SSNHL may result from vascular events such as microthrombi, which impair blood flow to the inner ear. While some studies have explored the use of anticoagulants, results have not been consistently supportive, and these treatments are typically reserved for patients with identified risk factors for vascular disease [23]. The patient discussed in this study did not present with obvious viral or vascular causes of hearing loss, and therefore antiviral or anticoagulant therapies were not pursued. This reflects current clinical practice, where these treatments are used selectively rather than as standard interventions for all SSNHL cases.

For patients who experience residual hearing loss despite pharmacologic and other treatments, rehabilitative strategies are critical in improving quality of life. Hearing aids and cochlear implants remain the primary rehabilitative options. For those with single-sided deafness, bone-anchored hearing aids (BAHA) offer a viable alternative to traditional devices, providing a solution that bypasses the damaged cochlea and transmits sound directly to the inner ear [24]. The patient in this case study showed significant improvement following medical treatment, reducing the need for rehabilitative devices. However, the role of audiologic rehabilitation should not be overlooked, as early intervention with hearing aids or implants can make a substantial difference in long-term outcomes for patients with more profound or permanent hearing loss.

While current treatment options for SSNHL show varying degrees of success, it is clear that there is no universally accepted protocol. Multimodal approaches are often necessary, with treatments tailored to the individual based on their response to therapy, comorbidities, and the severity of hearing loss. The case study presented in this document emphasizes the importance of early intervention, particularly with corticosteroids and other adjunct therapies, in maximizing the chances of recovery.

Moving forward, the integration of emerging therapies such as SGB, gene therapy, and HBOT with established

pharmacologic treatments holds promise for improving outcomes in SSNHL. However, the high costs associated with some of these treatments, as well as limited availability in certain healthcare settings, present challenges that need to be addressed. Moreover, more extensive clinical trials are needed to establish the efficacy of newer treatments like SGB and regenerative medicine, and to refine treatment protocols that will benefit the widest range of patients.

Conclusion

Despite the growing interest in SGB for SSNHL, more research is needed to fully understand its efficacy and optimal application. While anecdotal evidence and small clinical studies have shown potential benefits, larger, randomized controlled trials are required to establish its place in the treatment landscape for SSNHL. Additionally, the use of SGB should be considered carefully, as it may not be suitable for all patients, particularly those with contraindications to local anesthetics or steroids. In conclusion, SSNHL remains a challenging condition to treat, with no universally accepted protocol. However, multimodal approaches that include corticosteroids, intratympanic injections, HBOT, rehabilitative strategies, and emerging treatments like SGB offer hope for improving patient outcomes. Early diagnosis and intervention remain critical for maximizing the chances of hearing recovery. Although further research into the underlying causes of SSNHL, as well as the development of new therapeutic options, will be essential in advancing the treatment of this unpredictable condition, the current treatment approach used in this study was successful.

References

[1] Arslan N, Oguz H, Demirci M, Safak MA, Islam A, Kaytez SK, Samim E. Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss. Otology & Neurotology. 2011 Apr 1;32(3):393-7.

[2] Stachler RJ, Chandrasekhar SS, Archer SM, Rosenfeld RM, Schwartz SR, Barrs DM, Brown SR, Fife TD, Ford P, Ganiats TG, Hollingsworth DB. Clinical practice guideline: sudden hearing loss. Otolaryngology—Head and Neck Surgery. 2012 Mar;146(3_suppl):S1-35.

[3] Park YS, Jeon EJ. Intratympanic steroid therapy for sudden sensorineural hearing loss. Journal of Audiology & Otology. 2011;15(2):53-61.

[4] Lechner M, Sutton L, Ferguson M, Abbas Y, Sandhu J, Shaida A. Intratympanic steroid use for sudden sensorineural hearing loss: current otolaryngology practice. Annals of Otology, Rhinology & Laryngology. 2019 Jun;128(6):490-502.

[5] Joshua TG, Ayub A, Wijesinghe P, Nunez DA. Hyperbaric oxygen therapy for patients with sudden sensorineural hearing loss: a systematic review and meta-analysis. JAMA Otolaryngology–Head & Neck Surgery. 2022 Jan 1;148(1):5-11.

[6] Sherlock S, Thistlethwaite K, Khatun M, Perry C, Tabah A. Hyperbaric oxygen therapy in the treatment of sudden sensorineural hearing loss: a retrospective analysis of outcomes. Diving Hyperb Med. 2016 Sep 1;46(3):160-5.

[7] Stokroos RJ, Albers FW, Tenvergert EM. Antiviral treatment of idiopathic sudden sensorineural hearing loss: a prospective, randomized, double-blind clinical trial. Acta oto-laryngologica. 1998 Jan 1;118(4):488-95.

[8] Kallinen, Esa Laurikainen, Lasse Bergroth, Reidar Grénman J. A follow-up study of patients suffering from sudden sensorineural hearing loss. Acta oto-laryngologica. 2001 Jan 1;121(7):818-22.

[9] Carlsson PI, Hall M, Lind KJ, Danermark B. Quality of life, psychosocial consequences, and audiological rehabilitation after sudden sensorineural hearing loss. International Journal of Audiology. 2011 Feb 1;50(2):139-44.

[10] Stevenson J, McCann D, Watkin P, Worsfold S, Kennedy C, Hearing Outcomes Study Team. The relationship between language development and behaviour problems in children with hearing loss. Journal of Child Psychology and Psychiatry. 2010 Jan;51(1):77-83.

[11] Zhang W, Kim SM, Wang W, Cai C, Feng Y, Kong W, Lin X. Cochlear gene therapy for sensorineural hearing loss: current status and major remaining hurdles for translational success. Frontiers in molecular neuroscience. 2018 Jun 26;11:221.

[12] Ren H, Hu B, Jiang G. Advancements in prevention and intervention of sensorineural hearing loss. Therapeutic advances in chronic disease. 2022 Jun;13:20406223221104987.

[13] Eisenman D, Arts HA. Effectiveness of treatment for sudden sensorineural hearing loss. Archives of Otolaryngology–Head & Neck Surgery. 2000 Sep 1;126(9):1161-4.

[14] Abouzari M, Goshtasbi K, Chua JT, Tan D, Sarna B, Saber T, Lin HW, Djalilian HR. Adjuvant migraine medications in the treatment of sudden sensorineural hearing loss. The Laryngoscope. 2021 Jan;131(1):E283-8.

[15] Park KH, Lee CK, Lee JD, Park MK, Lee BD. Combination therapy with systemic steroids, an antiviral agent, anticoagulants, and stellate ganglion block for treatment of sudden sensorineural hearing loss. Korean Journal of Audiology. 2012 Sep;16(2):71.

[16] Han X, Yin X, Du X, Sun C. Combined intratympanic and systemic use of steroids as a first-line treatment for sudden sensorineural hearing loss: a meta-analysis of randomized, controlled trials. Otology & Neurotology. 2017 Apr 1;38(4):487-95.

[17] Kovács M, Uzsaly J, Bodzai G, Pap I, Lippai B, Dergez T, Németh A, Gerlinger I, Szanyi I, Bakó P. Efficacy of high dose systemic versus combined (systemic and intratympanic) corticosteroid therapy in idiopathic sudden sensorineural hearing loss: A prospective randomized trial and risk factor analysis. American Journal of Otolaryngology. 2024 Jan 1;45(1):104099.

[18] Choi Y, Han SJ, Kim SK, Hong SM. The therapeutic effect of hyperbaric oxygen therapy in patients with severe to profound idiopathic sudden sensorineural hearing loss. Scientific Reports. 2024 Feb 9;14(1):3321.

[19] Sanda N, Sawabe M, Kabaya K, Kawaguchi M, Fukushima A, Nakamura Y, Maseki S, Niwa M, Mori H, Hyodo Y, Nishiyama K. Clinical impact of hyperbaric oxygen therapy combined with steroid treatment for sudden sensorineural hearing loss: A case–control study. Laryngoscope Investigative Otolaryngology. 2024 Aug;9(4):e1297.

[20] Han SY, Lee J, Koo H, Chung J. Evaluation of effectiveness of stellate ganglion block treatment of sudden sensorineural hearing loss. Korean Journal of Otorhinolaryngology-Head and Neck Surgery. 2022 Feb 21;65(2):86-92.

[21] Mady OM, Ezzat WF, Askoura AM, Elbadawy GM. Stem cell therapy in sensorineural hearing loss: a systematic review. The Egyptian Journal of Otolaryngology. 2023 Oct 6;39(1):153.

[22] Chen X, Fu YY, Zhang TY. Role of viral infection in sudden hearing loss. Journal of International Medical Research. 2019 Jul;47(7):2865-72.

[23] Mierzwa K, Schneider G, Müller A. Sudden sensorineural hearing loss during oral anticoagulant therapy. The Journal of Laryngology & Otology. 2004 Nov;118(11):872-6.

[24] Linstrom CJ, Silverman CA, Yu GP. Efficacy of the bone-anchored hearing aid for single-sided deafness. The Laryngoscope. 2009 Apr;119(4):713-20.